Value is all about what a company is worth versus what price it is
available for. If you went into a grocery store and all the bananas were on sale
at half price, they could be considered
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
It is not possible to calculate the future cash flow value for
InMed Pharmaceuticals. This is due to cash flow or dividend data being
unavailable. The share price is
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for
it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing
when they are out of season, or how much your home is worth.
The amount the stock market is willing to pay for
is considered below, and whether this is a fair price.
Price based on past earnings
InMed Pharmaceuticals's earnings available for a low price, and how does
this compare to other companies in the same industry?
InMed Pharmaceuticals is not considered high growth as it is expected to be loss making for the next 1-3 years.
Unable to determine if InMed Pharmaceuticals is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can
be gauged below. We look back 3 years and see if they were any good at
predicting what actually occurred. We also show the highest and lowest estimates
looking forward to see if there is a wide range.
InMed Pharmaceuticals's performance over the past 5 years by checking for:
Has earnings increased in past 5 years? (1 check)
Has the earnings growth in the last year exceeded that of the
industry? (1 check)
Is the recent earnings growth over the last year higher than the average annual growth over the
past 5 years? (1 check)
Is the Return on Equity (ROE) higher than 20%? (1 check)
Is the Return on Assets (ROA) above industry average? (1 check)
Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent
earnings report. Some checks require at least 3 or 5 years worth of data.
has a total score of
0/6, see the detailed checks below.
Note: We use GAAP Net Income excluding extraordinary items in all our calculations.
A company's financial position is much like your own financial position,
it includes everything you own
The boxes below represent the relative size of what makes up
InMed Pharmaceuticals's finances.
The net worth of a company is the difference between its assets and liabilities.
InMed Pharmaceuticals is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
InMed Pharmaceuticals has no long term commitments.
This treemap shows a more detailed breakdown of
InMed Pharmaceuticals's finances. If any of them are yellow this
indicates they may be out of proportion and red means they relate to one of the
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
Low level of unsold assets.
InMed Pharmaceuticals has no debt, it does not need to be covered by short term assets.
Nearly all companies have debt. Debt in itself isn’t
however if the debt is too high, or the company can’t afford to pay the interest
on its debts this may have impacts in the future.
The graphic below shows equity (available funds) and debt, we ideally want to
see the red area (debt) decreasing.
If there is any debt we look at the companies capability to repay it, and
whether the level has increased over the past 5 years.
Management is one of the most important areas of a company. We look at
unreasonable CEO compensation, how long the team and board of directors have
been around for and insider trading.
TENURE AS CEO
Mr. Eric A. Adams, B.S. Chem., M.I.B. has been the Chief Executive Officer and President at InMed Pharmaceuticals Inc. since June 16, 2016. Mr. Adams served as a Strategic Advisor of Augurex Life Sciences Corp. He has more than 15 years of experience in pharmaceutical product development, commercialization and partnerships. Mr. Adams served as the Chief Executive Officer and President of enGene Inc., which he led from a nascent start-up to becoming a venture capital-backed leader in gene therapy. Mr. Adams worked with Fresenius AG (Germany) as a Country Manager for the U.S. and Italy and as Joint Venture/Acquisition Team Leader, where he expanded sales and distributions channels through numerous acquisitions and joint-ventures. He has held management positions in the pharmaceutical and biotechnology industry in North America and Europe with several companies, including Abbott Laboratories and was most recently with QLT Inc. in Vancouver. At the International Division of Abbott Laboratories, he served as Senior Business Development Manager for Anti-Infectives, where he managed all commercial, manufacturing, clinical and regulatory activities related to BIAXIN™, KLACID™. While at QLT, Mr. Adams served as the Director of Marketing for Oncology, where he managed several drug and device partnerships for Photofrin and developed new strategic opportunities through in-licensing. Previously, he served as Director of International Marketing at Advanced Tissue Sciences Inc., where he spearheaded international commercialization of Dermagraft-TC™ in the treatment of burn patients. He served as the Chairman of BIOTECanada's Emerging Company Advisory Board. He has been a Director at InMed Pharmaceuticals Inc. since June 16, 2016. Mr. Adams served as a Non Executive Director of enGene, Inc. since March 2004. Mr. Adams is well regarded in the Canadian biotech industry for his service as a strategic advisor to a number of early-stage biotech companies. He holds a Master of International Business from the University of South Carolina and a Bachelors in Chemistry from the University of Southern Indiana.
Eric's compensation has increased whilst company is loss making.
Eric's remuneration is higher than average for companies of similar size in Canada.
Management Team Tenure
Average tenure of the
management team in years:
The tenure for the InMed Pharmaceuticals management team is about average.
CFO & Corporate Secretary
Alexandra D. Mancini
Senior Vice President of Clinical & Regulatory Affairs
Chief Business Officer
Senior Vice President of Preclinical Research & Development
Co-Founder & Member of the Scientific Advisory Board
Vice President of Sales & Marketing
Senior Consultant of Medical affairs
Board of Directors Tenure
Average tenure and age of the
board of directors in years:
The average tenure for the InMed Pharmaceuticals board of directors is less than 3 years, this suggests a new board.
Board of Directors
Chairman of the Board
Co-Founder & Member of the Scientific Advisory Board
Should You Take Comfort From Insider Transactions At InMed Pharmaceuticals Inc. (TSE:IN)?
We often see insiders buying up shares in companies that perform well over the long term. … So we'll take a look at whether insiders have been buying or selling shares in InMed Pharmaceuticals Inc. … InMed Pharmaceuticals Insider Transactions Over The Last Year.
Is InMed Pharmaceuticals Inc (TSE:IN) A Volatile Stock?
If you're interested in InMed Pharmaceuticals Inc (TSE:IN), then you might want to consider its beta (a measure of share price volatility) in order to understand how the stock could impact your portfolio. … Beta can be a useful tool to understand how much a stock is influenced by market risk (volatility). … A stock with a beta greater than one is more sensitive to broader market movements than a stock with a beta of less than one.
Does InMed Pharmaceuticals Inc's (TSE:IN) Past Performance Indicate A Weaker Future?
After looking at InMed Pharmaceuticals Inc's (TSE:IN) latest earnings update (31 March 2018), I found it helpful to revisit the company's performance in the past couple of years and compare this against the latest numbers. … As a long-term investor I tend to focus on earnings trend, rather than a single number at one point in time. … IN is loss-making, with the most recent trailing twelve-month earnings of -CA$7.37m (from 31 March 2018), which compared to last year has become.
InMed Pharmaceuticals Inc., a pre-clinical stage biopharmaceutical company, researches and develops cannabinoid-based therapies. The company’s lead product is INM-750, a topical cannabinoid product candidate to treat epidermolysis bullosa. The company is also involved in developing INM-085, a cannabinoid-based topical therapy for glaucoma; and INM-405 for the treatment of orofacial pain. In addition, it engages in the development of drugs for the treatment of various diseases, including dermatology, ocular, pain, inflammation, cancer, and other disease areas. It has an agreement with Pharmaseed Ltd to develop a final formulation for INM-750; and work on IND-enabling pharmacology and toxicology studies. The company also has research agreement with the National Research Council of Canada in for biofermentation development and scale-up processes for cannabinoid biosynthesis in E.coli. The company was formerly known as Cannabis Technologies Inc. and changed its name to InMed Pharmaceuticals Inc. in October 2014. InMed Pharmaceuticals Inc. was incorporated in 1981 and is based in Vancouver, Canada.
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.